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The Muslim population is about 1.5 billion worldwide. Based on a global diabetes 
prevalence of 4.6%, it is estimated that there are about 50 million Muslims with dia-
betes around the world who observe fasting during the month of Ramadan each year. 
Ramadan, one of the five pillars of Islam, and which takes place during the ninth month 
of the Islamic calendar, involves fasting from sunrise to sunset. During the fast, Muslims 
are required to refrain from eating food, drinking, using medications, and smoking from 
dawn until after sunset, with no restrictions on food or fluid intake between sunset and 
dawn. Islam exempts people from the duty of fasting if they are sick, or if fasting may 
affect their health, as fasting for patients with diabetes carries a risk of an assortment 
of complications, including hypoglycemia, postprandial hyperglycemia, and metabolic 
complications, associated with dehydration. Nevertheless, a large number of people 
with diabetes who still choose to fast during Ramadan despite the advice of their doctor, 
and the permission received from religious authorities thus create medical challenges for 
themselves and their health-care providers. It is thus important for patients with diabetes 
who wish to fast during Ramadan to make the necessary preparations to engage in 
fasting as safely as possible. This review presents a guide to the care of diabetic patients 
during Ramadan to help them fast safely if they wish to do so.
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iNTRODUCTiON
The Muslim population is about 1.5 billion people worldwide. The approximate number of Muslims 
with diabetes is around 4.6%; we can estimate that more than 50 million people with diabetes mellitus 
observe fasting during the month of Ramadan (1, 2).
Healthy adult Muslims practice fasting from dawn until dusk during the month of Ramadan, 
which varies between 29 and 30 days. The duration of the daily fast may range from a few hours to 
more than 20 h, depending on the geographical location and season of the year.
During the fast, Muslims are required to abstain from consuming food orally, drinking, using 
medications, and smoking from dawn until after sunset. People usually eat two meals per day during 
the month of Ramadan – one after sunset and the other before dawn.
Islam exempts people from the duty of fasting if they are sick or if fasting may affect their health 
(3). Nevertheless, many people with diabetes still choose to fast during Ramadan against the advice 
of their doctors, as they perceive themselves as healthy and able to fast.
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Numerous studies that evaluated diabetic patients during 
Ramadan showed that there were little changes in patients’ 
glycemic control (4, 5). In one study, 76% of patients experi-
enced significant improvements in their fasting blood glucose 
levels during the fasting period (6). However, the results from the 
Epidemiology of Diabetes and Ramadan (EPIDIAR) study, which 
examined 12,243 patients, indicated that 78.7% of type 2 diabetes 
patients who fasted for at least 15 days during Ramadan were 7.5 
times more likely to exhibit an increase in their hypoglycemia, 
leading to hospitalization during the month of Ramadan when 
compared to the preceding months (7). Further evidence from 
a questionnaire survey conducted in Pakistan (which involved 
453 diabetic patients) shows that 72.2% of the study population 
fasted during the month of Ramadan for an average of 25 days (8). 
Recently, The Multi-Country Retrospective Observational Study 
of the Management and Outcomes of Patients with Diabetes dur-
ing Ramadan (the CREED study) of 3,250 patients reported that 
94% of patients with type 2 diabetes mellitus (T2DM) fast during 
Ramadan for a total of at least 15  days, with a mean number 
of 27 fasting days (9). On the other hand, researchers from the 
Benghazi Diabetes and Endocrine Centre (BDEC) study indi-
cated that hyperglycemic episodes were reported among 10.7% of 
493 T2DM patients who fast during Ramadan (10). Similarly, in a 
study of 682 patients with diabetes, the hyperglycemic symptoms 
were felt by 15.41% patients (of a total of 655) with T2DM (11). 
Also, the EPIDIAR study showed a fivefold increase in the occur-
rence of severe hyperglycemia during Ramadan in patients with 
T2DM (7).
Therefore, in people with type 2 diabetes, fasting increases 
the risk of both hypoglycemia and postprandial hyperglycemia 
(1, 12). Furthermore, a patient’s decision to cease taking medica-
tions, to skip or reduce the doses, or to take the medications at 
closer intervals without medical supervision increases the risk of 
such complications. Therefore, this emphasizes the need for close 
blood glucose monitoring, dietary modifications, and adequate 
nutrition.
Few studies have compared the efficacy and safety of differ-
ent antidiabetic agents in fasting patients during Ramadan. In 
one study, the risk of hypoglycemic events was significantly 
lower with a dipeptidyl peptidase (DPP)-4 inhibitor than with 
sulfonylurea (13). In another study, hypoglycemic control was 
achieved with repaglinide when compared with glibenclamide 
(14). There is no consensus as to what type of treatment can be 
given to T2DM patients who decide to fast during Ramadan due 
to their religious beliefs. Determining the best treatment strategy 
for T2DM patient who fast during Ramadan is a critical question.
The purposes of this review are to highlight the potential risks 
that may be associated with fasting during Ramadan, to increase 
awareness among medical professionals, and to improve their 
knowledge on how to manage their patients with diabetes who 
decide to fast during Ramadan.
MATeRiALS AND MeTHODS
This review included relevant English-language articles that 
were identified through searches of major databases, includ-
ing PubMed, Medline, and Embase (all, 1990–2015), using the 
keywords “Hyperglycemia, Ramadan, type 2 diabetes, pregnancy, 
insulin, and oral hypoglycemic agent.” Original research and 
review articles related to adult patients with diabetes mellitus 
were considered for the review.
eFFeCTS OF FASTiNG ON GLUCOSe 
MeTABOLiSM
In healthy people, insulin secretion decreases in response to the 
reduction of circulating glucose levels. At the same time, counter-
regulatory hormones (glucagon and catecholamines) rise, leading 
to a breakdown of glycogen (15). Since fasting is prolonged for 
several hours, the glycogen store becomes depleted, fatty acids 
release from the adipocytes, and ketones are subsequently 
generated, which serve as the fuel and sole source of energy for 
erythrocytes and for vital organs such as the brain. As the fasting 
hours in Ramadan only extends from dawn till dusk, there is good 
opportunity to replenish energy stores at sunset and dawn meals. 
This provides chance for transition from using glucose to fat as the 
sole source of energy and prevents protein breakdown in muscle. 
After a few days of fasting, better balance between levels of circu-
lating insulin and the counter-regulatory hormones is achieved; 
these factors maintain glucose levels within a normal range (16).
In individuals with diabetes, the balance between circulating 
levels of insulin and counter-regulatory hormones is defective. 
Therefore, prolonged fasting can lead to hyperglycemia and 
ketoacidosis as a result of excessive glycogen breakdown and 
increased gluconeogenesis and ketogenesis; however, ketoacido-
sis is uncommon in type 2 diabetic patients.
Several studies indicate that fasting during Ramadan neither 
does worsen a patient’s glycemic parameters nor does it alter the 
frequency of glycemic complications in patients with type 2 dia-
betes (17–19). In one study, significant improvements in fasting 
blood sugar were observed in 76% of patients during fasting (7), 
whereas other studies did not show this degree of improvement in 
glycemic control (5, 6). Similarly, the EPIDIAR study showed that 
hypoglycemia increased about ~7.5-fold in patients with type 2 
diabetes, and these patients had at least one episode of severe 
hyperglycemia requiring hospitalization, 4% of which occurred 
during Ramadan (7).
eFFeCTS OF FASTiNG ON LiPiD 
MeTABOLiSM
Several studies have shown no change or little decrease in 
cholesterol and triglyceride concentrations in patients with 
diabetes while fasting during Ramadan; conversely, high-
density lipoprotein (HDL) cholesterol concentrations tended 
to increase (18, 19).
ACUTe COMPLiCATiONS ASSOCiATeD 
wiTH RAMADAN FASTiNG iN DiABeTeS
Hypoglycemia
In people with diabetes, Ramadan fasting is a well-known risk 
factor for hypoglycemia given one’s abstinence from food. 
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Medications and participation in physical activity may increase 
the propensity for developing hypoglycemia. In a prospective 
cohort study, the relative risk of hypoglycemia in diabetics who 
fast during Ramadan was 1.6 when compared with non-fasting 
periods (20). Similarly, the EPIDIAR study noted that the risk 
of severe hypoglycemia increased by 7.5-fold in type 2 diabetes 
patients during Ramadan fasting (7). Finally, in the CREED study, 
the incidence of hypoglycemia during the month of Ramadan 
was reported in as few as 8.8% of patients, who reported at least 
one episode (9).
Hyperglycemia
In people with type 2 diabetes, prolonged fasting can lead to 
hyperglycemia and ketoacidosis due to excessive glycogen break-
down and increased gluconeogenesis and ketogenesis. However, 
ketoacidosis is uncommon in type 2 diabetic patients, while 
hyperglycemia severity usually depends on the extent to which 
insulin resistance or deficiency is present. The EPIDIAR study 
showed a fivefold increase in the incidence of severe hyperglyce-
mia (requiring hospitalization) during Ramadan in type 2 diabetic 
patients (7). Hyperglycemia may also be attributed to an excessive 
reduction of medication dosages to prevent hypoglycemia.
Dehydration and Thrombosis
Dehydration may be due to a number of causes. First, the reduced 
intake of fluids during fasting may cause dehydration, especially 
in cases of prolonged fasting and in hot climates. Second, exces-
sive urination due to hyperglycemia can result in volume and 
electrolyte depletion in the body. Patients may develop symp-
toms of low blood pressure, especially the one with autonomic 
neuropathy. A review of the available medical literature indicates 
that one’s body water status and electrolytes show slight changes 
during Ramadan. In normal individuals, urine volumes, as well 
as sodium and potassium concentrations, were lower and urinary 
osmolality was higher. However, patients’ urinary osmolality 
concentration was very high in the afternoon, indicating effective 
water conservation (21).
Studies have shown variable results regarding volume status 
and electrolyte changes in patients with diabetes during Ramadan. 
In one study, no significant difference in patients’ total body water 
was observed before or after the month of Ramadan (22).
Other studies have examined the effects of Ramadan fast-
ing on the hydration status of T2DM patients; a significant 
increase in urinary osmolality after 1  month of fasting was 
reported (23). With respect to serum sodium and potassium, 
no considerable changes occur during the fasting period in 
Ramadan (24). However, in another study, serum potassium 
concentration was reduced mainly in the morning, and its 
amount increased in the afternoon (25). Patient with diabetes 
have impaired fibrinolytic capacity as a result of elevated 
plasminogen activator inhibitor type 1 (26, 27). In addition 
to potentiating platelet function, these patients experience 
increases of tissue expression factors and plasma coagulation 
factors, such as factor VII, and a decrease in endogenous anti-
coagulants, such as antithrombin III (28, 29). Thus, diabetes is 
a hypercoagulable state, and it increases one’s tendency toward 
thrombosis, while it may also exacerbate the progression of 
atherosclerosis (30). Contraction of the intravascular space 
and dehydration during fasting may increase the risk of sinus 
venous thrombosis, stroke, and retinal vein occlusion (31, 32).
PRe-RAMADAN MeDiCAL ASSeSSMeNT 
AND eDUCATiON
It is worth re-emphasizing the measures that ensure patient safety 
during fasting in Ramadan. All patients with diabetes who wish 
to fast for Ramadan should receive a proper medical assessment, 
educational counseling, and appropriate blood testing 1–2 months 
before Ramadan to engage in the fast as safely as possible. Advice 
should focus on the potential risks of fasting, as well as on meal 
planning and medication regimen modification. The treatment 
plan should be individualized and educational counseling should 
include the patient’s family (33).
It is essential to understand that the use of insulin injections 
during Ramadan is permitted, as it offers no food value (34). 
Patients should monitor their blood glucose levels several times 
daily; this is particularly true among those who require insulin. 
Patients should be educated about the fact that puncturing the 
skin with glucose monitoring devices is allowed, and it does not 
affect one’s ability to fast. Furthermore, patients must take fluid 
liberally during non-fasting hours, and the last meal should be 
consumed as late as possible; the meal should contain complex 
carbohydrates, as this will delay digestion and absorption (35). 
All patients should maintain normal levels of activity and avoid 
insufficient sleep. Furthermore, they have to understand that they 
must end their fasting immediately if acute complications, such as 
hypoglycemia or hyperglycemia, occur (35).
MANAGeMeNT OF PATieNTS wiTH  
TYPe 2 DiABeTeS
Diet-Controlled Patients
Individuals whose type 2 diabetes is well controlled with diet and 
physical activity should be able to fast without problems, as the 
risks associated with fasting are low. However, if people eat exces-
sively following the predawn and sunset meals, there remains a 
potential risk for the occurrence of post-meal hyperglycemia. 
To prevent this problem, patients should divide their meals into 
two to three smaller meals during the non-fasting period, rather 
than consuming one big meal (36). Finally, a person involved in 
a regular exercise program may modify its intensity and timing 
to avoid hypoglycemia.
PATieNTS TReATeD wiTH ORAL 
HYPOGLYCeMiC AGeNTS
Biguanides (Metformin)
People who take metformin alone should be able to fast safely 
given that the possibility of hypoglycemia is minimal. However, 
patients should modify its dose and administration timing 
to provide two-thirds of the total daily dose, which should be 
taken immediately with the sunset meal, while the other third is 
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taken before the predawn meal (1, 12, 37). Patients treated with 
 slow-release formulations of metformin can take it once daily 
with the sunset meal (38).
Thiazolidinediones
Patients should be able to take thiazolidinediones (pioglita-
zone and rosiglitazone) as usual without dose adjustment, 
as the risk of hypoglycemia during fasting is low (36, 37). 
However, combination treatment requires a dose adjustment; 
one and half of the tablet should be taken immediately at the 
sunset meal, and the other half must be taken with the meal at 
dawn (37). These agents are characterized by their slow onset 
of action, perhaps taking as many as 8–12 weeks. Therefore, 
these agents cannot be substituted for other oral antidiabetics 
during Ramadan, as it takes many weeks for their actions to 
take effect (39).
Sulfonylureas
Individual treated with this group of drugs should be care-
ful during fasting because they face an increased risk of 
hypoglycemia. The use of glyburide or glibenclamide may 
be associated with a higher risk of hypoglycemia than other 
newer sulfonylureas, specifically gliclazide, glimepiride, and 
glipizide (40, 41).
Short-acting insulin secretagogues, such as repaglinide and 
nateglinide, have been shown to be effective with a low risk of 
hypoglycemia during the fasting period, particularly given their 
short duration of action. They can be taken twice daily before the 
sunset and predawn meals. In a study examining type 2 diabetes 
patients who fasted, it was found that the use of repaglinide was 
associated with a lower number of hypoglycemia events com-
pared with glibenclamide (14). In another study, 52 people with 
type 2 diabetes who fasted during Ramadan were randomized 
to receive either diet alone or a sulfonylurea (glimepiride or 
gliclazide MR once daily), or repaglinide. The authors concluded 
that repaglinide was associated with fewer hypoglycemia events 
when compared with sulfonylureas (42).
As a practical issue, individuals with diabetes who are treated 
with a once-daily sulfonylurea (such as glimepiride or gliclazide 
MR) should take the total daily dose with the sunset meal. If an 
individual takes a shorter acting sulfonylurea (such as gliclazide 
twice daily), the same daily dose remains unchanged, and the 
individual should take one dose at the sunset meal and the other 
at the predawn meal.
In the event that hypoglycemia occurs and persists during the 
day of Ramadan, the subject should reduce the predawn dose or 
stop it completely. Long-acting sulfonylureas, such as glibencla-
mide, should be avoided during fasting.
Glucosidase inhibitors
Individuals treated with glucosidase inhibitors (acarbose and 
miglitol) may safely fast because the risk of hypoglycemia is 
small. Changes in dose are usually not required (43). These agents 
decrease postprandial hyperglycemia but have limited efficacy. 
They are usually used in conjunction with other agents and cause 
frequent gastrointestinal side effects.
iNCReTiN-BASeD THeRAPY
DPP-4 inhibitors
DPP-4 inhibitors, such as alogliptin, saxagliptin, sitagliptin, 
and vildagliptin, are new oral hypoglycemic agents that act in a 
glucose-dependent manner and are associated with a minimal 
risk of hypoglycemia, although they can increase the hypoglyce-
mic effects of sulfonylureas. Patients should be able to take this 
medication during Ramadan with no dosage adjustment.
Two of these agents have been studied during Ramadan in 
diabetic patients. In a prospective study of 2,789 individuals 
with type 2 diabetes, they were inadequately controlled on 
metformin monotherapy. It was found that the incidence of 
hypoglycemia with vildagliptin was less when compared to 
glimepride (44).
Similarly, the VECTOR study, which featured 72 patients, 
showed no episodes of hypoglycemia with vildagliptin when 
compared with gliclazide in the setting of combination therapy 
with metformin in type 2 diabetic patients during Ramadan (45).
In one observational study, vildagliptin as an add-on to 
metformin was compared with gliclazide in patients with 
type 2 diabetes during Ramadan fasting. A significantly lower 
incidence of hypoglycemia was demonstrated with vildagliptin 
(13). Furthermore, in the VIRTUE study, which was conducted 
with 1,300 patients with T2DM fasting during Ramadan, vilda-
gliptin demonstrated significantly fewer hypoglycemic events 
than with sulfonylurea therapy (5.4 versus 19.8%, respectively; 
P < 0.001) (46).
In line with the results from previous studies, the randomized 
controlled study evaluating vildagliptin compared to gliclazide 
in patients with type 2 diabetes fasting during Ramadan 
(STEADFAST) showed that vildagliptin plus metformin is an 
effective and well-tolerated option in patients with T2DM during 
Ramadan, as it features a low incidence of hypoglycemia and 
similar efficacy to gliclazide plus metformin (47).
The use of sitagliptin during Ramadan has been studied in 
1,066 patients with type 2 diabetes. It was found that the risk of 
hypoglycemia was significantly lower with sitagliptin compared 
to those who remained on a sulfonylurea (48). More recently, a 
study involving 848 patients who fasted during Ramadan showed 
that sitagliptin reduced the risk of hypoglycemia by approximately 
50% when compared to sulfonylureas (49).
Glucagon-Like Peptide-1  
Receptor Agonists
This class of agents, which includes exenatide and liraglutide, is 
not independently associated with hypoglycemia; therefore, it 
may be suitable for Ramadan. However, these agents can increase 
the risk of hypoglycemia when combined with sulfonylureas and 
insulin; hence, the sulfonylurea or insulin dose may need to be 
reduced. It is important to note that when these agents are used 
alone during Ramadan, they do not require any dose adjustments 
(50). Glucagon-like peptide-1 (GLP-1) receptor agonists require 
dose titration, and they are associated with nausea and vomiting, 
particularly as therapy is initiated; this could be a limiting factor 
during fasting. Currently, there is not enough evidence regarding 
the use of these agents during Ramadan, although studies that did 
TABLe 1 | Recommended changes to the treatment regimen in patients 
with type 2 diabetes who fast during Ramadan.
Treatment Modification needed during Ramadan
Patients on diet and 
exercise
Distribute meals into 2–3 smaller meals, modify 
exercise intensity and timing, and ensure adequate 
fluid intake
Bigunide (metformin) Immediate-release formulations: two-thirds of the 
total daily dose should be taken immediately with 
the sunset meal and the other third taken before 
the predawn meal
Slow-release formulations: can be taken once daily 
with the sunset meal
Thiazolidinediones No change needed
Sulfonylurea Once-daily sulfonylurea (such as glimepiride or 
gliclazide MR): the total daily dose should be taken 
with the sunset meal
Shorter-acting sulfonylurea (such as gliclazide twice 
daily): the same daily dose remains unchanged, 
and one dose should be taken at the sunset meal 
and the other at the predawn meal
Long-acting sulfonylurea (such as glibenclamide): 
these agents should be avoided
Short-acting insulin 
secretagogues (repaglinide 
and nateglinide)
No change needed
Glucosidase inhibitors No change needed
DPP-4 inhibitors No change needed
GLP-1 analogs No change needed
Sodium glucose 
cotransporter 2 inhibitors 
(SGLT2 inhibitors)
There are no studies of these agents during periods 
of fasting, so their use is not recommended, or they 
should be used with caution
Insulin Multiple daily injections: long-acting insulin at 
sunset with 20% reduction of the dose. For  
pre-meal insulin, omit the afternoon dose and take 
the morning dose at the time of the sunset meal, 
and take half of the evening dose at dawn
Premixed insulin: morning dose should be taken 
at the sunset meal and half of the evening dose 
should be taken at dawn
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not assess patients during Ramadan did show that these agents 
cause fewer hypoglycemic events (similar to monotherapies) 
when compared to conventional treatments. Recently, The Treat 
4 Ramadan study was the first randomized controlled trial to 
compare liraglutide with sulfonylureas use in top of metformin 
among 99 T2DM patients. That study showed that there were 
significantly fewer hypoglycemic episodes in the liraglutide arm. 
The author concluded that liraglutide is well tolerated, and it 
may even be an effective therapy when used in combination with 
metformin during Ramadan (51).
Sodium Glucose Co-Transporter 2 
inhibitors
Sodium glucose co-transporter 2 inhibitors represent new agents 
with a unique mode of action that improves glycemic control by 
decreasing the renal reabsorption of glucose; these agents do not 
cause hypoglycemia (52). They offer a safe option for patients who 
fast during Ramadan without compromising glycemic control. 
However, there are no studies of these agents during periods 
of fasting. Trials to examine the safety and tolerability of these 
agents during Ramadan would be beneficial.
insulin
The glycemic control of patients with type 2 diabetes during 
Ramadan should be individualized. Patients treated with 
insulin usually face the same problems as those with type 1 
diabetes, except for the fact that the incidence of hypoglycemia 
is lower. Moreover, patients with T2DM also need to maintain 
a high enough level of basal insulin to prevent fasting hyper-
glycemia. An effective strategy for patients using multiple daily 
injections would be to administer long-acting insulin with a 
meal at sunset and to reduce the dose by 20% to reduce the risk 
of hypoglycemia (53). For insulin taken before meals, patients 
should omit the afternoon dose and take the morning dose at 
the sunset meal; they should also take half of the evening dose 
at dawn.
Rapid-acting insulin analogs (when compared to regular 
human insulin) before meals is associated with a lower incidence 
of hypoglycemia and minimal postprandial hyperglycemia 
(53–55). The use of these newer insulin analog preparations 
during fasting may be more useful, as regular human insulin has 
a long-lasting peak with a high possibility of late postprandial 
hyperglycemia (55).
Another important note is that when using premixed insulin, 
the patient should take the morning dose at the sunset meal and 
half of the evening dose at dawn (50, 53, 56). If patients take the 
once-daily premixed insulin before Ramadan, then the same dose 
should be taken before the sunset meal (57), with further insulin 
dose titration performed based on home blood glucose data.
DiABeTiC MeDiCATiON ADJUSTMeNT 
DURiNG RAMADAN
The summary and recommendations for adjusting therapy dur-
ing Ramadan in patients with type 2 diabetes are illustrated in 
Table 1.
MANAGeMeNT OF HYPOGLYCeMiA 
DURiNG FASTiNG
Diabetic patients who insist on fasting during Ramadan should 
be aware of the risk hypoglycemia; they should receive appropri-
ate advice to decrease this potential risk. The most crucial issue 
is that the patients should have ability to monitor their blood 
glucose levels several times daily, which is especially critical for 
patients who require insulin. Those with diabetes should eat a 
healthy, balanced diet, and avoid overeating, especially at sunset. 
It is also advisable that the last meal be taken as late as possible 
and with an adequate amount of fluid during the non-fasting 
hours. Moreover, diabetic patients should maintain normal 
levels of activity, as excessive physical activity  –  particularly 
during the few hours before sunset – may lead to hypoglycemia. 
It is essential that patients end their fasting immediately if hypo-
glycemia [blood glucose of <60 mg/dL (3.3 mmol/L)] occurs, 
as their blood glucose levels may drop further if they delay 
treatment. Obviously, given the increased risk of hypoglycemia 
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during Ramadan, one should adjust the treatment regimen 
accordingly.
LiFeSTYLe iNTeRveNTiONS AND 
eDUCATiON DURiNG FASTiNG
Ramadan-focused education and lifestyle modifications should 
be re-enforced before and during Ramadan to minimize the 
risk of hypoglycemic events and the occurrence of post-meal 
hyperglycemia. In one study, patients who did not attend an edu-
cational program had a fourfold increased risk of hypoglycemic 
events, whereas those who attended the program had a significant 
decrease in these events (33). It is essential that diabetic patients 
who want to fast should continue to monitor their blood glucose 
levels several times throughout the day; this is particularly critical 
for those who require insulin.
It is important that diabetic patients eat a healthy balanced 
diet and that they choose foods with a low glycemic index (such 
as complex carbohydrates), which can help to maintain blood 
glucose levels during fasting. Moreover, it is crucial to consume 
adequate fluid to prevent dehydration. Physical activity is encour-
aged, especially during non-fasting periods. Prayers after sunset 
should be considered as part of the daily exercise program. Family 
members should receive adequate and appropriate education on 
self-care and diabetes management during Ramadan to minimize 
any negative effects that might result from fasting.
PReGNANCY AND FASTiNG DURiNG 
RAMADAN
Pregnancy involves a state of increased resistance and insulin 
secretion. In healthy pregnant women, fasting blood glucose levels 
are low, while postprandial glucose and insulin remain high when 
compared to non-pregnant women. Pregnant Muslim women are 
exempt from fasting during Ramadan; however, some choose to 
fast due to their personal beliefs or religious commitments.
Fasting during pregnancy is believed to carry a high risk of 
morbidity and mortality to both the fetus and the mother (58). 
Therefore, it is strongly recommended that pregnant women not 
fast during Ramadan. The management of pregnant patients dur-
ing Ramadan includes providing an appropriate pre-Ramadan 
assessment and education to ensure that the required diet and 
insulin dose adjustment are in place. These patients should also 
be monitored more frequently.
DiABeTeS MANAGeMeNT AFTeR 
RAMADAN
A 3-day festival “Eid ul-Fitr” follows the month of Ramadan. This 
is usually characterized by the sharing of food and sweet bever-
ages. The management of Muslim people with diabetes during 
this period of time continues to be a challenge, as many patients 
overindulge in eating and drinking. Diabetic education during 
this time is an essential tool to prevent potential complications 
such as hypoglycemia, hyperglycemia, and diabetic ketoacidosis. 
It is critical that diabetic patients are well informed to monitor 
their blood glucose levels several times daily, to avoid overeating, 
and to adjust their medications; patients may be changed to their 
previous regimen if their glycemic control was optimal before the 
month of Ramadan (53).
CONCLUSiON
Managing diabetic patients during Ramadan continues to be a 
challenge. It is crucial that health-care providers are able to offer 
advice and counseling to diabetic patients to help them fast safely, 
if they wish to do so. It is important to individualize each patient’s 
management plan depending on his or her diet and lifestyle, 
medications, risk of hypoglycemia, and glycemic control, and to 
minimize the complications associated with fasting. The practical 
management of these patients is made based on the knowledge 
of carbohydrate metabolism and on hormonal changes during 
pregnancy, as well as on the pharmacology of various antidiabetic 
drugs. In general, the risk of hypoglycemia and hyperglycemia 
in patients with type 2 diabetes is not overly common, and it is 
associated less severe consequences.
Further studies are needed to help expand our knowledge 
concerning all the factors that affect blood glucose control during 
this period.
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